Introduction:
Guillain–Barré syndrome (GBS) is an immune-related disorder with an estimated annual incidence of 1-2 cases per 100,000 worldwide. It is the most common cause of acute non-trauma related paralysis in the developed world1. It manifests as acute, rapidly progressing polyradiculoneuropathy due to inflammation and demyelination of the peripheral nervous system, resulting in a classically symmetrical and ascending weakness, often in association with hyporeflexia or areflexia2. The exact cause of Guillain–Barre syndrome is still unknown, but the suggested pathophysiology is molecular mimicry following respiratory and gastrointestinal infections.
After the first case was reported in Wuhan, China in December 2019, the global pandemic caused by SARS-CoV-2 brought many challenges including the manufacturing and administration of vaccine. Several vaccines were approved by FDA and reported side effects ranged from pain at the site of injection, myalgia, fatigue, and fever to more serious ones including anaphylaxis3,4. GBS was linked with some vaccines namely, rabies, hepatitis A and B, polio and influenza5. However, a causative relationship was not established.